Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1632-1635, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parsy, D.
Right arrow Articles by Fruchart, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parsy, D.
Right arrow Articles by Fruchart, J. C.

Clinical Chemistry, Vol 31, 1632-1635, Copyright © 1985 by American Association for Clinical Chemistry

Quantification of apolipoprotein C-III in serum by a noncompetitive immunoenzymometric assay

D Parsy, V Clavey, C Fievet, I Kora, P Duriez and JC Fruchart

We used a noncompetitive immunoenzymometric assay to measure the concentration of total apolipoprotein C-III in human sera. Affinity- purified antibodies to apolipoprotein C-III were adsorbed to the surface of microtiter plates. After washing, this solid-phase antibody was incubated with antigen (serum from fasting subjects), washed, and then incubated with peroxidase-labeled purified antibodies to apolipoprotein C-III. After a last washing, the bound label was assayed, providing a direct measurement of the antigen. Optimized technical conditions for the assay yielded assay CVs of 3.5 and 5.6% for within- and between-run precision, respectively. Analytical recovery of apolipoprotein C-III added to a serum was quantitative (97%). This noncompetitive assay can be used to measure apolipoprotein C-III in different lipoprotein fractions (very-low or high-density fractions) and yields values that compare favorably with those obtained by electroimmunoassay (r = 0.94). The assay offers several advantages over existing techniques--sensitivity, specificity, simplicity, and no use of radioisotopes--and hyperlipemic samples can be used.


The following articles in journals at HighWire Press have cited this article:


Home page
 J CARDIOVASC PHARMACOL THERHome page
J. Dallongeville, J.-C. Fruchart, P. Maigret, S. Bertolini, G. Bittolo Bon, M. M. Campbell, M. Farnier, J. Langan, G. Mahla, P. Pauciullo, et al.
Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 103 - 110.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
N. Helbecque, J. Dallongeville, V. Codron, D. Arveiler, J.-B. Ruidavets, A. Evans, F. Cambien, J.-C. Fruchart, and P. Amouyel
The Role of a Triplet Repeat Sequence of the Very Low Density Lipoprotein Receptor Gene in Plasma Lipid and Lipoprotein Level Variability in Humans
Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2759 - 2764.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.